CClinicalTrials.gg
Status unknownNCT05678751Updated Jan 10, 2023

Rapid Detection Method for Microorganisms in the Lower Genital Tract

An observational study in Infertility, Female, sponsored by Shenzhen Second People's Hospital. Status unknown. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Shenzhen Second People's Hospital · Observational

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
228
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Mycoplasma, chlamydia, and gonococcal infection of the female lower genital tract can lead to infertility and various adverse pregnancy outcomes. The lower genital tract bacterial community status type (CST) is closely related to genital tract infection and reproductive health. However, there is a need for a rapid, accurate, stable, and economical detection method to detect the above pathogens and CST at the same time, so there is also a need for evaluation of the correlation between each pathogen infection and CST. Matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) is more stable and accurate than traditional detection methods such as culture and staining. It can simultaneously detect a variety of microorganisms and their subtypes, while the high-throughput sequencing method is faster and more economical, which is suitable for detecting multiple microorganisms in clinical practice. The research group has established a perfect MALDI-TOF MS platform in the early stage and put it into clinical testing. This project will establish a new rapid detection method for lower genital tract microorganisms based on MALDI-TOF MS. Then, examine the lower genital tract microecology of infertile patients and healthy women using the newly developed method. At last, analyze the correlation between pathogen infection, CST status, and infertility. This project will solve the practical work needs of clinicians for a comprehensive assessment of female lower genital tract CST and common pathogen infection and fill in the technical gaps in the microbial examination of the lower genital tract.

02

Conditions studied

  • Infertility, Female
03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's planned enrollment of 228 is above the median of 200 across 714 observational studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Shenzhen Second People's Hospital is the lead sponsor of 48 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women of childbearing age who can spontaneous pregnancy and infertile women

Inclusion criteria

Case group:

  1. Female aged 18-40 2) Regular menstrual cycle 2) Conform to the clinical diagnosis of infertility 3) No sexual life 3 days before the examination control group:
  1. Female aged 18-40
  2. Regular menstrual cycle
  3. Patients who did pre-pregnancy consultation in our hospital, pregnant at the time of 3-month follow-up
  4. No sexual life 3 days before the examination -

Exclusion criteria

Exclusion Criteria:

Case group:

  1. Infertility due to malformation of reproductive tract
  2. Infertility caused by endocrine factors such as polycystic ovary syndrome, premature ovarian failure and severe hyperthyroidism
  3. Infertility due to male factors
  4. Patients with malignant tumors
  5. Patients with autoimmune diseases
  6. Patients with severe heart, kidney and other basic diseases
  7. Patients who consumed antibiotics 3 days before the examination
  8. Have the habit of smoking and drinking

Control group:

  1. Pregnancy by various assisted reproductive means
  2. Patients with malignant tumors
  3. Patients with autoimmune diseases
  4. Patients with severe heart, kidney and other basic diseases
  5. Patients who consumed antibiotics 3 days before the examination
  6. Have the habit of smoking and drinking
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
228 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • case group

    patients with infertility

    Diagnostic Test: lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)

  • control group

    women that are capable of spontaneous intrauterine pregnanc

    Diagnostic Test: lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)

Interventions

  • Diagnostic testlower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)

    Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique

06

What researchers measure

Primary outcomes

  1. Lower genital tract pathogen

    Ureaplasma urealyticum, mycoplasma hominis, chlamydia antigen, gonococcus

    Time frame: at recruitment

  2. Lower genital CST

    Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus iners, Lactobacillus jensenii

    Time frame: at recruitment

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chen YJ, Hsu TF, Huang BS, Tsai HW, Chang YH, Wang PH. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol. 2017 Jun;216(6):582.e1-582.e9. doi: 10.1016/j.ajog.2017.02.008. Epub 2017 Feb 15. PubMed 28209488 ↗
  • Carey AJ, Beagley KW. Chlamydia trachomatis, a hidden epidemic: effects on female reproduction and options for treatment. Am J Reprod Immunol. 2010 Jun;63(6):576-86. doi: 10.1111/j.1600-0897.2010.00819.x. Epub 2010 Feb 28. PubMed 20192953 ↗
  • Chee WJY, Chew SY, Than LTL. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microb Cell Fact. 2020 Nov 7;19(1):203. doi: 10.1186/s12934-020-01464-4. PubMed 33160356 ↗
  • Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017 Jan 15;595(2):451-463. doi: 10.1113/JP271694. Epub 2016 May 5. PubMed 27373840 ↗
  • Dunlop AL, Satten GA, Hu YJ, Knight AK, Hill CC, Wright ML, Smith AK, Read TD, Pearce BD, Corwin EJ. Vaginal Microbiome Composition in Early Pregnancy and Risk of Spontaneous Preterm and Early Term Birth Among African American Women. Front Cell Infect Microbiol. 2021 Apr 29;11:641005. doi: 10.3389/fcimb.2021.641005. eCollection 2021. PubMed 33996627 ↗

Study documents

  • Protocol and statistical analysis plan · Jun 15, 2022
  • Informed consent form · Jun 14, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — Because this study involves private information related to patient reproduction, we may not fully disclose subject details, but we will evaluate applicants and give non-private data by email, etc., when necessary.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05678751
Lead sponsor
Shenzhen Second People's Hospital
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Jan 2023 (estimated)
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jan 10, 2023

Study contacts

Yu Chen, M.D.
Contact
chenyu2017@email.szu.edu.cn
+86 0755 83366388 ext. 3048
Zhiying Yu, M.D.
study chair · Shenzhen Second People's Hospital
Wenlan Liu, PhD
study director · Shenzhen Second People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion